Designing Better GLP-1 Drug Delivery: From Molecular Structure to Advanced Formulations
GLP-1 drug delivery has advanced through structural modifications and formulation innovations to overcome the natural peptide's rapid degradation by DPP-IV.
Quick Facts
What This Study Found
Various structural modifications and delivery strategies have successfully overcome GLP-1's fragility, enabling the development of long-acting and orally available GLP-1 therapeutics.
Key Numbers
Reviews N-terminal, C-terminal, fatty acid side chain, and large molecule conjugation modifications. Discusses half-life extension, receptor binding, and bioactivity improvements.
How They Did This
Comprehensive review of GLP-1 structural biology, DPP-IV resistance strategies, pharmacokinetic modifications, and advanced drug delivery formulation approaches.
Why This Research Matters
Understanding how GLP-1 drugs were engineered explains why different formulations exist and informs the development of next-generation versions with even better convenience and efficacy.
The Bigger Picture
The GLP-1 drug development story is a masterclass in peptide engineering — turning a fragile natural hormone into one of the most successful drug classes in medicine.
What This Study Doesn't Tell Us
Review article — does not provide new experimental data. Some discussed delivery approaches are still experimental.
Questions This Raises
- ?What delivery innovations will enable the next generation of GLP-1 drugs?
- ?Can implantable or long-acting depot formulations extend dosing to monthly or beyond?
Trust & Context
- Key Stat:
- Minutes to weeks Structural and delivery innovations extended GLP-1 drug activity from minutes (native peptide) to once-weekly dosing
- Evidence Grade:
- Comprehensive review of established and emerging drug delivery science. Well-supported by decades of published research.
- Study Age:
- Published in 2025, providing an up-to-date overview of GLP-1 delivery technology including the latest formulation advances.
- Original Title:
- Designing GLP-1 delivery: structural perspectives and formulation approaches for optimized therapy.
- Published In:
- Nutrition & diabetes, 15(1), 53 (2025)
- Database ID:
- RPEP-13024
Evidence Hierarchy
Summarizes existing research without a strict systematic method.
What do these levels mean? →Frequently Asked Questions
Why cannot you just swallow natural GLP-1?
Natural GLP-1 is destroyed by the enzyme DPP-IV within minutes and would also be degraded by digestive enzymes if swallowed. The drugs available today use chemical modifications to resist these enzymes, and special formulations (like oral semaglutide) use absorption enhancers to survive the gut.
Will there be monthly or longer-acting GLP-1 drugs?
Research is moving in that direction. Advanced delivery systems including implants and depot formulations are being developed that could extend dosing intervals beyond weekly, improving convenience for patients.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-13024APA
Peri, Ravi Vamsi; Anchan, Harsh; Jonnalagadda, Kamal; Varghese, Ryan; Gupta, Pardeep. (2025). Designing GLP-1 delivery: structural perspectives and formulation approaches for optimized therapy.. Nutrition & diabetes, 15(1), 53. https://doi.org/10.1038/s41387-025-00397-4
MLA
Peri, Ravi Vamsi, et al. "Designing GLP-1 delivery: structural perspectives and formulation approaches for optimized therapy.." Nutrition & diabetes, 2025. https://doi.org/10.1038/s41387-025-00397-4
RethinkPeptides
RethinkPeptides Research Database. "Designing GLP-1 delivery: structural perspectives and formul..." RPEP-13024. Retrieved from https://rethinkpeptides.com/research/peri-2025-designing-glp1-delivery-structural
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.